GDC 0853

Drug Profile

GDC 0853

Alternative Names: Bruton’s tyrosine kinase inhibitor - Genentech; GDC-0853; RG 7845; RO 7010939

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Antirheumatics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase I Autoimmune disorders
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 05 May 2017 Hoffmann-La Roche plans a phase II trial for Urticaria (NCT03137069)
  • 31 Dec 2016 Phase-II clinical trials in Systemic lupus erythematosus (Combination therapy) in USA, Bulgaria, South Korea, Spain, Taiwan, Portugal, Germany, United Kingdom (PO) (NCT02908100; EudraCT2016-001039-11)
  • 01 Dec 2016 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment, Treatment-experienced) in Russia, Ukraine (PO) (NCT02983227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top